Efficacy and safety of addition of minor bloodletting (petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections

Journal of Gastroenterology

Volumn 44, Issue 6, 2009, Pages 577-582

  Tanaka, Naoki ^a,b   Horiuchi, Akira ^c   Yamaura, Takahiro ^d   Komatsu, Michiharu ^b   Yokoyama, Takahide ^b   Okaniwa, Shinji ^d   Nagaya, Tadanobu ^b   Yoshizawa, Kaname ^b   Kiyosawa, Kendo ^e   Aoyama, Toshifumi ^a   Tanaka, Eiji ^b  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Showa Inan General Hospital   (Japan)

^d Iida Municipal Hospital   (Japan)

^e NAGANO RED CROSS HOSPITAL   (Japan)

Author keywords

Albumin; Ferritin; Glycyrrhizin injection; Hepatitis C; Liver cirrhosis; Petit phlebotomy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; FERRITIN; GLYCYRRHIZIC ACID;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG SAFETY; FAINTNESS; FEMALE; FERRITIN BLOOD LEVEL; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PATIENT SAFETY; PERIPHERAL EDEMA; PETIT PHLEBOTOMY; PHLEBOTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS; BLOODLETTING; COMBINED MODALITY THERAPY; FEMALE; FERRITINS; GLYCYRRHIZIC ACID; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67449099875     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0034-x     Document Type: Article

References (14)

1. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671-5.
2. Tarao K, Rino Y, Ohkawa S, Endo O, Miyakawa K, Tamai S, et al. Sustained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of Child stage A. Intervirology. 2004;47:65-71.
3. Tanaka N, Kiyosawa K. Phlebotomy: A promising treatment for chronic hepatitis C. J Gastroenterol. 2004;39:601-3.
4. Kaito M. Molecular mechanism of iron metabolism and overload in chronic hepatitis C. J Gastroenterol. 2007;42:96-9.
5. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol. 1994;89:986-8.
6. Yano M, Hayashi H, Yoshioka K, Kohgo Y, Saito H, Niitsu Y, et al. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: A multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol. 2004;39:570-4.
7. Tanaka N, Horiuchi A, Yamaura T, Komatsu M, Tanaka E, Kiyosawa K. Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: A pilot study. J Gastroenterol. 2007;42:49-55.
8. Tanaka N, Tanaka E, Sheena Y, Komatsu M, Okiyama W, Misawa N, et al. Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. Liver Int. 2006;26:956-63.
9. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol. 2008;42:413-8.
10. Tanaka N, Nagaya T, Komatsu M, Horiuchi A, Tsuruta G, Shirakawa H, et al. Insulin resistance and hepatitis C virus: A case-control study of non-obese, non-alcoholic and non-steatotic hepatitis virus carriers with persistently normal serum aminotransferase. Liver Int. 2008;28:1104-11.
11. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Tsubota A, Suzuki F, et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection: Practical discriminant function using common laboratory data. Hepatol Res. 2000;18:252-66.
12. Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T, et al. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: A cohort study of 1249 patients. Dig Dis Sci. 2006;51:603-9.
13. Kato J, Kobune M, Nakamura T, Kuroiwa G, Takada K, Takimoto R, et al. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 2001;61:8697-702.
14. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol. 2007;42:830-6.